BPH Flashcards
normal size prostate gland
-<20g
-growth is common after age 40
Benign Prostatic Hypertrophy mech
-a-1 receptors
-NE stimulation results in contraction
=narrowing of urethra
-type-II 5-a reductase
type II 5-a reductase
-in prostate gland
-testosterone to DHT
=prostate growth
Obstructive BPH symptoms
-dec force of stream
-hesitancy to initiate pissing
-strain/push to pee
-terminal dribbling
-intermittency
Irritative BPH symptoms
-nocturia
-freq
-urgency
-dysuria
-incontinence
-QOL
Nocturia
-2 or more pisses/night
-redistribution of edma
BPH diagnosis
-symptoms + exam
-measure flow rate
-measure residual volume
-AUA symptom score
Complications of BPH
-chronic renal failure
-overflow urinary incontinence
-recurrent UTIs
-diminished QOL
Role of pharmacist in BPH
-advise on OTC
-encourage evaluation
-advice on use
-screen for potential ADRs from meds
Treatment of mild (AUA<7) BPH
-watchful waiting
Treatment of mod (AUA 8-19) BPH w ED
-a-antagonist
-PDE-5 inhibitor
-or both
Treatment of mod (AUA 8-19) BPH w small prostate and low PSA
-a-adrenergic antagonist
Treatment of mod (AUA 8-19) BPH w large prostate and inc PSA
-5a-reductase inhibitor +/- a-antagonist
Treatment of mod (AUA 8-19) BPH w predominant irritative voiding symptoms
-a-antagonist
-anticholinergic agent
Treatment of severe BPH (>20)
-minimally invasive surgery
-prostatectomy
Goals of BPH therapy
-control symptoms
-dec AUA by at least 3 pts
-prevent complications
-delay need for surgery
Non-pharma treatment of BPH
-avoid drugs w strong anti-cholinergic properties (=urinary retention)
-antihistamines, tricyclic antidepressants, cogentin, artane, scopolamine, anti muscarinics
BPH non-drug therapy
-restrcit fluid, alcohol and caffeine intake in pm
-avoid diuretics and nasal decongestants if possible
-use kegel exercises
BPH + OAB treatment
-a-antagonist + anti-muscarinic
avoid anti-muscarinics in
BPH pts w residual > 200 ml or max flow rate of < 5mL/sec
Mild drug therapy of BPH
-CAM therapy
-Saw Palmetto 160 mg bid (iffy efficacy but some anti-androgenic activity)
moderate BPH therapy
-non-drug measures
-alpha blockers +/-
-hormone therapy
-PDE inhibtiors
secere BPH therapy
-consider invasive treatment
A-1a adrenergic blockade
-developed for HTN
-relax smooth muscle of prostate gland and bladder (improves flow)
-does NOT reduce size of prostate gland
-onset 1-6 weeks
-dec AUA score 30-40%